![JSR_image_042517.png JSR_image_042517.png](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/blt1b93f467dfe2e9cc/658d76c2b424af040a101c54/JSR_image_042517.png?width=700&auto=webp&quality=80&disable=upscale)
Currently more than 70 biosimilar mAbs (monoclonal antibodies) are under development and multiple originator mAbs are going off-patent in the next 3-4 years. Protein A resin remains the most important workhorse for the purification of monoclonal antibodies.
Protein A resin has a high impact on both development and manufacturing cost,
in particular during early stage clinical phases. This application note summarizes the key performance parameters for our high capacity protein A resin, Amsphere A3, for 6 biosimilar molecules of which five are mAbs and one is a Fc-fusion protein.